Yazar "Yiğenoğlu, Tuğçe Nur" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The Timing of Granulocyte Colony-Stimulating Factor in Hematopoietic Stem Cell Transplant in the Pandemic
    (Yuzuncu Yil Universitesi Tip Fakultesi, 2023) Kaçmaz, Murat; Başci, Semih; Yiğenoğlu, Tuğçe Nur; Çakar, Merih Kizil; Dal, Mehmet Sinan; Altuntaş, Fevzi
    Granulocyte-colony stimulating factors (G-CSF) are used to shorten the duration of neutropenia after hematopoietic cell transplantation (HCT). However, there is no consensus on which days treatment should be started post-transplantation during the COVID-19 pandemic. In this study, we looked at the influence of G-CSF on clinical outcomes on the fifth (G-CSFd5) and tenth (G-CSFd10) days following allo-HCT. Our study includes the data of 60 patients (G-CSFd5, n=28 vs G-CSFd10, n=32) who underwent HCT with the diagnosis of acute lymphoblastic leukemia (ALL) between 2015 and 2022. Primary outcome is the effect of G-CSF on hospital stay. Secondary outcomes are the development and duration of febrile neutropenia (FEN), neutrophil engraftment (NE), platelet engraftment (PE), engra ftment syndrome (ES), acute graft versus host disease (aGVHD), cytomegalovirus (CMV) viremia, and effects on antimicrobial use . Length of hospital stay, 34.5 days vs. 30 days (p=0.19); median NE, 13.85 vs 15.03 days (p=0.007); median PE, 15.5 vs 12 days (p =0.12); ES, 28.5% vs 12.5% (p=0.12); FEN, 85.7% vs 84.3% (p=0.88); aGVHD, 39.2% vs 40.6% (p=0.92); were observed for G-CSFd5 and G-CSFd10, respectively. Although starting G-CSF in the early period after allo-HCT shortened the duration of NE, positive effects on clinical outcomes were not observed. On the contrary, the frequency of ES increased in the group that received GCSF early. © 2023, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
  • Küçük Resim
    Öğe
    Uric Acid and Multiple Myeloma, Unexplored Association
    (2023) Kaçmaz, Murat; Başcı, Semih; Yaman, Samet; Candir, Burcu Aslan; Seçilmiş, Sema; İlhan, Gül; Yiğenoğlu, Tuğçe Nur
    Introduction: Multiple Myeloma (MM) is a common hematological malignancy and various factors affect survival. Uric acid (UA) is an easily and quickly accessible laboratory test. UA has been found to affect prognosis and survival in many hematological diseases and its impact on myeloma is not widely investigated. Methods: Our retrospective study includes 106 MM patients between 2014 and 2021. The influence of UA level at diagnosis on treatment outcomes and survival of patients who received autologous stem cell transplantation (ASCT) was investigated. Results: The mean UA at diagnosis was 6.05 mg/dL, and 38.7% of our cohort relapsed after a median of 30 months of follow-up, with 22.7% dead. In survival analysis, the level of UA did not significantly differ in both progression-free survival (PFS) and overall survival (OS) (HR, 1.067; 95% CI, 0.947-1.202; p=0.290, HR, 0.941; 95% CI, 0.791-1.121; p=0.497, respectively). Discussion and Conclusion: In our study, regardless of the cut-off value for the UA level at the time of diagnosis, the UA level had no impact on PFS or OS in MM patients who received ASCT.